Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
Gary M. Gallego(Theravance Biopharma (United States)), Sajiv K. Nair(Pfizer (United States)), Sacha Ninkovic(Pfizer (United States)), Louise Bernier(Pfizer (United States)), Julie Cianfrogna(Pfizer (United States)), John C. Kath(Pfizer (United States)), Lars Anders(Pfizer (United States)), Robert S. Kania(RG Biopharma (United States)), Aida Sacaan(Pfizer (United States)), Loretta M. Cox(Pfizer (United States)), Bernadette Pascual(Pfizer (United States)), Na Wei(Pfizer (United States)), Lisa D. Marroquin(Pfizer (United States)), Judith G. Deal(Pfizer (United States)), Britton Boras(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Mehran Jalaie(Pfizer (United States)), Neal W. Sach(Pfizer (United States)), Sujin Cho-Schultz(Pfizer (United States)), Casey L. Quinlan(Pfizer (United States)), Suvi T. M. Orr(Tracon Pharmaceuticals (United States)), Fengjuan Cao(Pfizer (United States)), Klaus Dress(Pfizer (United States)), Eric F. Johnson(Pfizer (United States)), Hong Shen(Pfizer (United States)), Cynthia L. Palmer(Pfizer (United States)), Ping Chen(Shandong Jiaotong University), Jennifer Lafontaine(Pfizer (United States)), Matthew D. Petroski(Pfizer (United States))
Cited by 4
Related Papers
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
|Cancer Research|2008|2k
ABC transporters: the power to change
|Nature Reviews Molecular Cell Biology|2009|1.4k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models
|Clinical Cancer Research|2007|770